ClinicalTrials.gg
Drug

Adebrelimab clinical trials

Also written SHR-1316 and HTI-1088.

studies test it
205
open now
184
in phase 3
18
first study started
2017

How each study uses adebrelimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the adebrelimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Adebrelimab
89
Adebrelimab Injection
10
Adebrelimab (PD-L1 inhibitor)
4
SHR-1316 Injection
3
HAIC
2

Development codes

SHR-1316
32
HTI-1088
4

In one entry with another drug

Given together, or one or the other

Adebrelimab + Apatinib
5
SHR-A2102 ; Adebrelimab injection
2

Studies by the year they started

204 studies that test it; most in 2024 (77)

Studies that test adebrelimab, by start year
YearStudies
20171
20183
20204
20213
20226
202319
202477
202545
202646

Who runs them

Industry 44 · Other 161

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (18) · Fudan University (13) · Tianjin Medical University Cancer Institute and Hospital (11) · Jiangsu HengRui Medicine Co., Ltd. (9) · Shanghai Hengrui Pharmaceutical Co., Ltd. (7) · The First Affiliated Hospital with Nanjing Medical University (7) · Sun Yat-sen University (6) · Peking University Cancer Hospital & Institute (6)

Often tested with

Tested in the same studies.

Apatinib (29) · Trastuzumab rezetecan (18) · Paclitaxel (8) · Anti-CTLA-4 Monoclonal Antibody SHR-8068 (7) · KRAS G12D Inhibitor HRS-4642 (7) · Antineoplastic Agents (7) · Notiretatug rezetecan (7) · SHR-1701 (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 58, 1 in phase 3

Studies that test adebrelimab, phase 3 first.

Studies

Open first, then newest update. How each study uses adebrelimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 205

See all 205 studies that test adebrelimab →

Given beside what is tested · 52 — adebrelimab is usual care or a partner of the new treatment

Showing 20 of 52.

As the comparator · 3 — what is tested is compared with adebrelimab

What changed recently

From the registry's own updates since Oct 17, 2026.

Codes

What other systems call adebrelimab · ClinicalTrials.gg INT014364

  • UNII (FDA) 1XBY50W1OXADEBRELIMABOne source FDA
  • NCI Thesaurus C148535AdebrelimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.